NEUTRALIZING AND T CELL RESPONSE AGAINST MPOX VIRUS AFTER MVA-BN VACCINE
Background: Modified vaccinia Ankara-Bavarian Nordik (MVA-BN) was licensed for Mpox. Recent data estimated single dose effectiveness around 78%, whereas its ability to induce neutralising antibodies (nAbs) has been measured as relatively low. Whether historical smallpox vaccination (HiSXV) or HIV infection may impact MVA-BN response remains to be determined. Methods: Blood samples collected from participants (pts)…